新型冠状病毒抗体检测及中和性抗体免疫治疗研究进展  

Advances in the antibody detection and immunotherapy of neutralizing antibodies for 2019-nCoV

作　　者：袁梦娇 王蓓丽 潘柏申 郭玮 Yuan Mengjiao;Wang Beili;Pan Baishen;Guo Wei(Department of Laboratory Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院检验科,上海200032

出　　处：《中华检验医学杂志》2021年第3期265-269,共5页Chinese Journal of Laboratory Medicine

基　　金：复旦大学附属中山医院青年科学基金(18ZSQN43);上海市优秀青年医技人才(201702);上海市临床重点专科建设项目(医学检验科)。

摘　　要：2019年12月新发现的新型冠状病毒肺炎(COVID-19)已被列为国际公共卫生紧急事件。核酸检测在确诊新型冠状病毒(2019-nCoV)感染中具有不可替代的作用,但由于其对实验室和技术人员要求高、操作繁琐以及存在“漏检”可能等,应联合特异性抗体对疑似患者和密切接触人群实现大规模批量筛查,且抗体的检测可降低医务人员在呼吸道标本采集过程中的暴露风险。A novel coronavirus(COVID-19)that broke out in December 2019 has been declared a public health emergency of international concern.Nucleic acid detection has an irreplaceable role in the diagnosis of 2019-novel coronavirus(2019-nCoV)infection.However,due to the high requirements of laboratories and technicians,cumbersome operations,and the possibility of omission,nucleic acid detection should be combined with specific antibodies to achieve large-scale screening of suspected patients and close contacts.Moreover,antibody detection can reduce the exposure risk of medical personnel during the collection of respiratory tract samples.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 中和性抗体 

分 类 号：R563.1[医药卫生—呼吸系统]